A consultation with a PlexusDx clinician can clarify whether your timeline and goals align with short-term use or whether sustained, genetically-guided therapy offers better outcomes
Post fiscal year end, Lexaria raised an additional $7.5 million gross that should fund the company for 2026
Michael White, Distinguished Professor of Pharmacy Practice, issued a warning to consumers about the potential undisclosed risks of these off-brand products: High demand is driving GLP-1 wannabes The dietary supplement market has sought to cash in on the GLP-1 demand with pills, teas, extracts and all manner of other products that claim to produce similar effects as the brand names at a much lower price
But an older, insulin-resistant person eating a low-volume version of the standard American diet may lose muscle, facial support, and skin quality simultaneously
Corticosteroid optimisation : working with the rheumatology team to use the lowest effective dose or explore steroid-sparing agents may help reduce medication-related weight gain